Vladimir S Kostic

List of Publications by Year
in descending order

126	2,800	218677	233421
papers	citations	26 h-index	45 g-index

133	133	133	4611
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinsonâ€™s disease patients. Journal of Neurology, 2022, 269, 1485-1500.	3.6	24
2	Autosomal recessive adultÂonset ataxia. Journal of Neurology, 2022, 269, 504-533.	3.6	5
3	Functional MRI connectivity of the primary motor cortex in functional dystonia patients. Journal of Neurology, 2022, 269, 2961-2971.	3.6	6
4	Functional connectivity in Parkinsonâ€™s disease candidates for deep brain stimulation. Npj Parkinson's Disease, 2022, 8, 4.	5.3	9
5	Neurogenetic traits outline vulnerability to cortical disruption in Parkinsonâ€™s disease. NeuroImage: Clinical, 2022, 33, 102941.	2.7	4
6	Adherence to Medication among Parkinsonâ€™s Disease Patients Using the Adherence to Refills and Medications Scale. International Journal of Clinical Practice, 2022, 2022, 1-7.	1.7	2
7	The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 7-12.	2.2	1
8	Longitudinal White Matter Damage Evolution in Parkinson's Disease. Movement Disorders, 2022, 37, 315-324.	3.9	16
9	Clinical exome sequencing in Serbian patients with movement disorders: Single centre experience. Genetika, 2022, 54, 395-409.	0.4	1
10	Longitudinal brain connectivity changes and clinical evolution in Parkinsonâ€™s disease. Molecular Psychiatry, 2021, 26, 5429-5440.	7.9	39
11	Brain Structural Changes in Focal Dystoniaâ€"What About Task Specificity? A Multimodal <scp>MRI</scp> Study. Movement Disorders, 2021, 36, 196-205.	3.9	33
12	The Profile and Evolution of Neuropsychiatric Symptoms in Multiple System Atrophy: Self- and Caregiver Report. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 124-131.	1.8	4
13	Brain structural alterations in patients with GCH1 mutations associated DOPA-responsive dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 332-333.	1.9	2
14	Oxidative Stress Profile in Genetically Confirmed Cases of Leberâ€™s Hereditary Optic Neuropathy. Journal of Molecular Neuroscience, 2021, 71, 1070-1081.	2.3	9
15	Premutations in the FMR1 gene in Serbian patients with undetermined tremor, ataxia and parkinsonism. Neurological Research, 2021, 43, 321-326.	1.3	1
16	Linking Penetrance and Transcription in <scp>DYTâ€THAP1</scp>: Insights From a Human <scp>iPSC</scp>â€Derived Cortical Model. Movement Disorders, 2021, 36, 1381-1391.	3.9	14
17	PHACTR1 genetic variability is not critical in small vessel ischemic disease patients and PcomA recruitment in C57BL/6J mice. Scientific Reports, 2021, 11, 6072.	3.3	2
18	Clinical and Genetic Analysis of Psychosis in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1973-1980.	2.8	4

#	Article	IF	Citations
19	Perspectives on the pharmacological management of dystonia. Expert Opinion on Pharmacotherapy, 2021, 22, 1555-1566.	1.8	0
20	Autonomic nervous systemâ€"Anatomy, physiology, biochemistry. International Review of Movement Disorders, 2021, , 1-17.	0.1	0
21	Mutational Analysis and mtDNA Haplogroup Characterization in Three Serbian Cases of Mitochondrial Encephalomyopathies and Literature Review. Diagnostics, 2021, 11, 1969.	2.6	2
22	NBIA Syndromes: A Step Forward from the Previous Knowledge. Neurology India, 2021, 69, 1380-1388.	0.4	6
23	Are there two different forms of functional dystonia? A multimodal brain structural MRI study. Molecular Psychiatry, 2020, 25, 3350-3359.	7.9	22
24	Spatiotemporal gait characteristics of Huntingtonâ€™s disease during dual-task walking. International Journal of Neuroscience, 2020, 130, 136-143.	1.6	5
25	Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant. Journal of Neurology, 2020, 267, 87-94.	3.6	24
26	Dynamics of impulsiveâ€“compulsive behaviors in early Parkinsonâ€™s disease: a prospective study. Journal of Neurology, 2020, 267, 1127-1136.	3.6	15
27	Analysis of secondary mtDNA mutations in families with Leberâ€™s hereditary optic neuropathy: Four novel variants and their association with clinical presentation. Mitochondrion, 2020, 50, 132-138.	3.4	9
28	In silico model of mtDNA mutations effect on secondary and 3D structure of mitochondrial rRNA and tRNA in Leberâ€™s hereditary optic neuropathy. Experimental Eye Research, 2020, 201, 108277.	2.6	2
29	Progressive brain atrophy and clinical evolution in Parkinsonâ€™s disease. NeuroImage: Clinical, 2020, 28, 102374.	2.7	33
30	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. Journal of Parkinson's Disease, 2020, 10, 1833-1843.	2.8	3
31	Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease. Movement Disorders, 2020, 35, 1987-1998.	3.9	39
32	Whole Mitochondrial Genome Analysis in Serbian Cases of Leberâ€™s Hereditary Optic Neuropathy. Genes, 2020, 11, 1037.	2.4	4
33	Screening for gene mutation in early onset Alzheimerâ€™s disease and frontotemporal dementia: Report from a Serbian tertiary referral center. Alzheimer's and Dementia, 2020, 16, e041807.	0.8	0
34	Breakdown of the affectiveâ€cognitive network in functional dystonia. Human Brain Mapping, 2020, 41, 3059-3076.	3.6	16
35	Novel PANK2 mutation identified in patient with pantothenate kinase-associated neurodegeneration. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 203-206.	0.2	0
36	Changes of Phenotypic Pattern in Functional Movement Disorders: A Prospective Cohort Study. Frontiers in Neurology, 2020, 11, 582215.	2.4	5

#	Article	IF	Citations
37	Analysis of on-surface and in-air movement in handwriting of subjects with Parkinsonâ€™s disease and atypical parkinsonism. Biomedizinische Technik, 2019, 64, 187-194.	0.8	7
38	Artificial intelligence for assisting diagnostics and assessment of Parkinsonâ€™s diseaseâ€”A review. Clinical Neurology and Neurosurgery, 2019, 184, 105442.	1.4	110
39	Longitudinal assessment of autonomic dysfunction in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 74-79.	2.2	40
40	An Expert System for Quantification of Bradykinesia Based on Wearable Inertial Sensors. Sensors, 2019, 19, 2644.	3.8	25
41	AMP-activated protein kinase inhibits MPP+-induced oxidative stress and apoptotic death of SH-SY5Y cells through sequential stimulation of Akt and autophagy. European Journal of Pharmacology, 2019, 863, 172677.	3.5	16
42	10Kin1day: A Bottom-Up Neuroimaging Initiative. Frontiers in Neurology, 2019, 10, 425.	2.4	15
43	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
44	Chemical management of levodopa-induced dyskinesia in Parkinsonâ€™s disease patients. Expert Opinion on Pharmacotherapy, 2019, 20, 219-230.	1.8	16
45	Change in fear of falling in Parkinson's disease: a two-year prospective cohort study. International Psychogeriatrics, 2019, 31, 13-20.	1.0	7
46	Phenotypic expression and founder effect of PANK2 c.1583C>T (p.T528M) mutation in Serbian pantothenate kinase-associated neurodegeneration patients. Archives of Biological Sciences, 2019, 71, 275-280.	0.5	1
47	Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology, 2018, 90, e707-e716.	1.1	29
48	Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 696-701.	1.9	18
49	Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 353-360.	3.3	12
50	Progression of white matter damage in progressive supranuclear palsy with predominant parkinsonism. Parkinsonism and Related Disorders, 2018, 49, 95-99.	2.2	13
51	Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 38-44.	1.8	12
52	Characteristics of two distinct clinical phenotypes of functional (psychogenic) dystonia: follow-up study. Journal of Neurology, 2018, 265, 82-88.	3.6	10
53	P2â€311: EARLY ONSET DEGENERATIVE DEMENTIAS: ETIOLOGICAL CLASSIFICATION AND DEMOGRAPHIC CHARACTERISTICS IN SERBIAN TERTIARY REFERRAL CENTER. Alzheimer's and Dementia, 2018, 14, P801.	0.8	0
54	Functional and structural brain networks in posterior cortical atrophy: A two-centre multiparametric MRI study. NeuroImage: Clinical, 2018, 19, 901-910.	2.7	23

#	Article	IF	Citations
55	Factors associated with deterioration of health-related quality of life in multiple system atrophy: 1-year follow-up study. Acta Neurologica Belgica, 2018, 118, 589-595.	1.1	6
56	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
57	Finger and foot tapping sensor system for objective motor assessment. Vojnosanitetski Pregled, 2018, 75, 68-77.	0.2	11
58	Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges. CNS and Neurological Disorders - Drug Targets, 2018, 16, 927-935.	1.4	3
59	Brain Calcification and Movement Disorders. Current Neurology and Neuroscience Reports, 2017, 17, 2.	4.2	18
60	Role of habenula and amygdala dysfunction in Parkinson disease patients with punding. Neurology, 2017, 88, 2207-2215.	1.1	32
61	Is there a specific psychiatric background or personality profile in functional dystonia?. Journal of Psychosomatic Research, 2017, 97, 58-62.	2.6	12
62	Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementia. NeuroImage: Clinical, 2017, 15, 428-438.	2.7	49
63	Structural Brain Connectome and Cognitive Impairment in Parkinson Disease. Radiology, 2017, 283, 515-525.	7.3	77
64	GCH1 mutations are common in Serbian patients with dystonia-parkinsonism: Challenging previously reported prevalenceÂrates of DOPA-responsive dystonia. Parkinsonism and Related Disorders, 2017, 45, 81-84.	2.2	13
65	Near-falls in people with Parkinson's disease: Circumstances, contributing factors and association with falling. Clinical Neurology and Neurosurgery, 2017, 161, 51-55.	1.4	29
66	Dynamics of change in self-reported disability among persons with Parkinsonâ€™s disease after 2Âyears of follow-up. Neurological Sciences, 2017, 38, 1415-1421.	1.9	8
67	White matter tract alterations in Parkinson's disease patients with punding. Parkinsonism and Related Disorders, 2017, 43, 85-91.	2.2	22
68	Selection of gait parameters for differential diagnostics of patients with de novo Parkinsonâ€™s disease. Neurological Research, 2017, 39, 853-861.	1.3	24
69	[P1â€“563]: REPORT FROM BELGRADE DEMENTIA CENTER: A STEP TOWARD IMPROVING THE QUALITY OF DIAGNOSTICS AND TREATMENT OF DEMENTIA PATIENTS IN CLINICAL PRACTICE. Alzheimer's and Dementia, 2017, 13, P510.	0.8	0
70	Influence of attention alternation on movement-related cortical potentials in healthy individuals and stroke patients. Clinical Neurophysiology, 2017, 128, 165-175.	1.5	13
71	[P3â€“223]: GENETIC MUTATIONS IN EARLYâ€ONSET DEMENTIA: REPORT FROM THE MEMORY CLINIC FROM SERBIA. Alzheimer's and Dementia, 2017, 13, P1023.	0.8	0
72	Quantification of Finger-Tapping Angle Based on Wearable Sensors. Sensors, 2017, 17, 203.	3.8	22

#	Article	IF	Citations
73	Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients. Human Genomics, 2017, 11, 30.	2.9	21
74	Spectral parameters for finger tapping quantification. Facta Universitatis - Series Electronics and Energetics, 2017, 30, 585-597.	0.9	2
75	Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients. Disease Markers, 2016, 2016, 1-9.	1.3	31
76	Healthâ€related quality of life as a predictor of recurrent falling in Parkinson's disease: 1â€year followâ€up study. Psychogeriatrics, 2016, 16, 362-367.	1.2	7
77	Excellent outcome of pallidal deep brain stimulation in DYT6 dystonia: A case report. Journal of the Neurological Sciences, 2016, 366, 18-19.	0.6	9
78	Finger tapping analysis in patients with Parkinsonâ€™s disease and atypical parkinsonism. Journal of Clinical Neuroscience, 2016, 30, 49-55.	1.5	37
79	Seemingly dominant inheritance of a recessiveANO10mutation in romani families with cerebellar ataxia. Movement Disorders, 2016, 31, 1929-1931.	3.9	12
80	HPCA-related dystonia: Too rare to be found?. Movement Disorders, 2016, 31, 1071-1071.	3.9	9
81	Neuropsychiatric symptoms in Serbian patients with Parkinson's disease. Journal of the Neurological Sciences, 2016, 367, 342-346.	0.6	11
82	Indoor and outdoor falls in persons with Parkinsonâ€™s disease after 1Âyear follow-up study: differences and consequences. Neurological Sciences, 2016, 37, 597-602.	1.9	22
83	The clinical syndrome of dystonia with anarthria/aphonia. Parkinsonism and Related Disorders, 2016, 24, 20-27.	2.2	10
84	Efficient neuroplasticity induction in chronic stroke patients by an associative brain-computer interface. Journal of Neurophysiology, 2016, 115, 1410-1421.	1.8	189
85	Glucocerebrosidase and parkinsonism: lessons to learn. Journal of Neurology, 2016, 263, 1033-1044.	3.6	6
86	The role of mutations in COL6A3 in isolated dystonia. Journal of Neurology, 2016, 263, 730-734.	3.6	15
87	Brain structural changes in spasmodic dysphonia: A multimodal magnetic resonance imaging study. Parkinsonism and Related Disorders, 2016, 25, 78-84.	2.2	24
88	Recurrent falls in Parkinsonâ€™s disease after one year of follow-up: A nested case-control study. Archives of Gerontology and Geriatrics, 2016, 65, 17-24.	3.0	19
89	Psychiatric Symptoms in the Initial Motor Stage of Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2016, 28, 205-210.	1.8	7
90	Brain structural and functional connectivity in <scp>P</scp>arkinson's disease with freezing of gait. Human Brain Mapping, 2015, 36, 5064-5078.	3.6	154

#	Article	IF	Citations
91	Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	13
92	Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population. Journal of the Neurological Sciences, 2015, 353, 59-62.	0.6	7
93	Pattern of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN) â€“ Prospective study. Parkinsonism and Related Disorders, 2015, 21, 521-524.	2.2	18
94	The spread of primary late-onset focal dystonia in a long-term follow up study. Clinical Neurology and Neurosurgery, 2015, 132, 41-43.	1.4	18
95	Presenting symptoms of GBA-related Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 804-807.	2.2	14
96	Health-related quality of life in patients with Parkinson's disease: Implications for falling. Parkinsonism and Related Disorders, 2015, 21, 573-576.	2.2	11
97	Phenotype of non-c.907_909delGAG mutations in TOR1A: DYT1 dystonia revisited. Parkinsonism and Related Disorders, 2015, 21, 1256-1259.	2.2	21
98	Quality of life in patients with progressive supranuclear palsy: one-year follow-up. Journal of Neurology, 2015, 262, 2042-2048.	3.6	22
99	Cognitive Impairment in Myotonic Dystrophy Type 1 Is Associated with White Matter Damage. PLoS ONE, 2014, 9, e104697.	2.5	76
100	C9orf72 expansion as a possible genetic cause of Huntington disease phenocopy syndrome. Journal of Neurology, 2014, 261, 1917-1921.	3.6	34
101	Attentional Set-Shifting in Parkinsonâ€™s Disease Patients with Freezing of Gait-Acquisition and Discrimination Set Learning Deficits at the Background?. Journal of the International Neuropsychological Society, 2014, 20, 929-936.	1.8	15
102	Mutations inGNAL. JAMA Neurology, 2014, 71, 490.	9.0	70
103	Leber hereditary optic neuropathy in the population of Serbia. European Journal of Paediatric Neurology, 2014, 18, 354-359.	1.6	14
104	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Movement Disorders, 2014, 29, 857-867.	3.9	193
105	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiology of Disease, 2014, 63, 1-11.	4.4	97
106	Mutations in Niemann Pick type C gene are risk factor for Alzheimerâ€™s disease. Medical Hypotheses, 2014, 83, 559-562.	1.5	17
107	Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism. Neurobiology of Aging, 2014, 35, 2592-2602.	3.1	77
108	Gait characteristics in patients with major depression performing cognitive and motor tasks while walking. Psychiatry Research, 2014, 217, 39-46.	3.3	32

#	Article	IF	Citations
109	Circumstances of falls and fall-related injuries among patients with Parkinson's disease in an outpatient setting. Geriatric Nursing, 2014, 35, 364-369.	1.9	42
110	O2-07-06: DISTINCT NEUROPSYCHOLOGICAL AND BEHAVIOURAL PROFILES IN EARLY-ONSET ALZHEIMER'S DISEASE: REPORT FROM BELGRADE MEMORY CLINIC. , 2014, 10, P179-P179.		0
111	Quantitative and qualitative gait assessments in Parkinsonâ€™s disease patients. Vojnosanitetski Pregled, 2014, 71, 809-816.	0.2	8
112	Reversible lesions in the brain parenchyma in Wilsonâ€²s disease confirmed by magnetic resonance imaging: earlier administration of chelating therapy can reduce the damage to the brain. Neural Regeneration Research, 2014, 9, 1912.	3.0	11
113	The potential of imagination and artificial afference in stroke rehabilitation. , 2012, , .		0
114	Transcranial sonography in pantothenate kinase-associated neurodegeneration. Journal of Neurology, 2012, 259, 959-964.	3.6	20
115	Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanitetski Pregled, 2012, 69, 1067-1075.	0.2	7
116	Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanitetski Pregled, 2012, 69, 1067-75.	0.2	3
117	Neuroanatomical correlates of depression and apathy in Parkinson's disease: Magnetic resonance imaging studies. Journal of the Neurological Sciences, 2011, 310, 61-63.	0.6	58
118	Exclusion of linkage to chromosomes 14q, 2q37 and 8p21.1-q11.23 in a Serbian family with idiopathic basal ganglia calcification. Journal of Neurology, 2011, 258, 1637-1642.	3.6	19
119	Reply: MRI measurements of brain stem structures in patients with Richardson's syndrome, progressive supranuclear palsyâ€“parkinsonism, and Parkinson's disease. Movement Disorders, 2011, 26, 1575-1576.	3.9	1
120	Suicide and suicidal ideation in Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 40-43.	0.6	67
121	Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists. Parkinsonism and Related Disorders, 2009, 15, S71-S75.	2.2	21
122	Intrafamilial phenotypic and genetic heterogeneity of dystonia. Journal of the Neurological Sciences, 2006, 250, 92-96.	0.6	16
123	Bereitschaftspotential in depressed and non-depressed patients with Parkinson's disease. Movement Disorders, 2001, 16, 294-300.	3.9	9
124	The Status of SCA1, MJD/SCA3, FRDA, DRPLA and MD Triplet Containing Genes in Patients with Huntington Disease and Healthy Controls. Journal of Neurogenetics, 2000, 14, 257-263.	1.4	9
125	Multiple Sclerosis as the Cause of Sudden â€˜Pontineâ€™ Deafness. International Journal of Audiology, 1994, 33, 195-201.	1.7	24
126	Function of dopamine receptors in young-onset parkinson's disease: Prolactin response. Movement Disorders, 1993, 8, 227-229.	3.9	7